Acquired drug resistance · adults with drug‐sensitive pulmonary tuberculosis
It is very uncertain whether gatifloxacin‐containing 4‐month ATT regimens changes acquired drug resistance compared with standard 6‐month ATT regimens (very low certainty).
1 finding from 1 review
Change in Hb level · anaemia in predialysis patients
1 finding from 1 review
Adverse events: RBC transfusions · anaemia in predialysis patients
Epoetin alfa every four weeks showed no clear difference in adverse events: RBC transfusions compared with with every two weeks (low certainty).
1 finding from 1 review
Adverse events: hypertension · anaemia in predialysis patients
Epoetin alfa every four weeks showed no clear difference in adverse events: hypertension compared with with every two weeks (moderate certainty).
1 finding from 1 review
Adverse events: arteriovenous complications · anaemia in predialysis patients
Epoetin alfa every four weeks showed no clear difference in adverse events: arteriovenous complications compared with with every two weeks (low certainty).
1 finding from 1 review
Final Hb · anaemia in predialysis patients
1 finding from 1 review
Mean weekly epoetin dose · anaemia in predialysis patients
1 finding from 1 review
Deaths · anaemia in predialysis patients
Epoetin theta showed no clear difference in deaths compared with epoetin beta (low certainty).
1 finding from 1 review
Adverse events: hypertension · anaemia in predialysis patients
Epoetin theta showed no clear difference in adverse events: hypertension compared with epoetin beta (moderate certainty).
1 finding from 1 review
Adverse events: RBC transfusions · anaemia in predialysis patients
Epoetin theta showed no clear difference in adverse events: RBC transfusions compared with epoetin beta (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · anaemia in predialysis patients
Epoetin theta showed no clear difference in adverse events: discontinuation of therapy compared with epoetin beta (low certainty).
1 finding from 1 review
Number reaching target Hb · anaemia in predialysis patients
Epoetin alpha every 2 weeks may leads to lower number reaching target Hb compared with to weekly (low certainty).
1 finding from 1 review
Number of deaths · anaemia in predialysis patients
Epoetin alpha every 2 weeks showed no clear difference in number of deaths compared with to weekly (low certainty).
1 finding from 1 review
Adverse events: RBC transfusions · anaemia in predialysis patients
Epoetin alpha every 2 weeks showed no clear difference in adverse events: RBC transfusions compared with to weekly (low certainty).
1 finding from 1 review
Adverse events: hypertension · anaemia in predialysis patients
Epoetin alpha every 2 weeks showed no clear difference in adverse events: hypertension compared with to weekly (moderate certainty).
1 finding from 1 review
Adverse events: thrombovascular events · anaemia in predialysis patients
Epoetin alpha every 2 weeks showed no clear difference in adverse events: thrombovascular events compared with to weekly (low certainty).
1 finding from 1 review
Change in Hb level · anaemia in predialysis patients
1 finding from 1 review
Number reaching target Hb · anaemia in predialysis patients
It is very uncertain whether epoetin alfa every four weeks changes number reaching target Hb compared with with every two weeks (very low certainty).
1 finding from 1 review
Number of deaths · anaemia in predialysis patients
Epoetin alfa every four weeks showed no clear difference in number of deaths compared with with every two weeks (low certainty).
1 finding from 1 review
Neonatal mortality · promoting growth and development in very low birth weight infants receiving human milk
Supplemental vitamin A showed no clear difference in neonatal death compared with no supplementation (moderate certainty).
1 finding from 1 review